CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05945823
Title field or adapter rule: {'original_value': 'A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors.', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:26.781631+00:00
Published At: 2026-09-01T00:00:00+00:00
Record Updated At: 2026-09-01
Source Retrieved At: 2026-10-31T22:17:58.991924+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Cancer", "Siewert Type 1 GEJ Cancer", "Pancreatic Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-09-01", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT05945823"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors."
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['Cohort A', 'Cohort B'], 'description': 'TAS-120 20 mg tablets, oral; once daily', 'name': 'Futibatinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort A', 'Cohort B'], 'description': '400 mg once every 6-week-cycle, via IV infusion.', 'name': 'Pembrolizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort A'], 'description': "80 mg/m\\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy", 'name': 'Cisplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort A', 'Cohort B'], 'description': "4000 mg/m\\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\\^2 Q2W via bolus IV infusion followed by 2400 mg/m\\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.\n\n2400 mg/m\\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.\n\n2400 mg/m\\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy.", 'name': '5-FU', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort A', 'Cohort B'], 'description': '85 mg/m\\^2 Q2W via IV infusion, as part of mFOLFIRINOX or mFOLFOX6 chemotherapy. 2400 mg/m\\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy.', 'name': 'Oxaliplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort A', 'Cohort B'], 'description': '400 mg/m\\^2 Q2W as part of mFOLFIRINOX or mFOLFOX6 chemotherapy.', 'name': 'Leucovorin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort A', 'Cohort B'], 'description': "200 mg/m\\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.", 'name': 'Levoleucovorin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort B'], 'description': '150 mg/m\\^2 Q2W as part of mFOLFIRINOX chemotherapy.', 'name': 'Irinotecan', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.